Abstract
Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have limited treatment options. Venetoclax is a potent BCL-2 inhibitor that induces apoptosis in CLL cells. This open-label, phase 1/2 study (NCT02265731) evaluated the safety, pharmacokinetics, and efficacy of venetoclax in Japanese patients with R/R CLL/SLL. Patients enrolled in phase 1 received 400 mg/day venetoclax monotherapy. Patients enrolled in phase 2 received 400 mg/day venetoclax, plus rituximab. Venetoclax was administered with a weekly stepwise ramp-up in doses. In phase 2, efficacy was evaluated by objective response rate (ORR). Twelve patients were enrolled, six in each arm. The most common grade ≥ 3 adverse events were neutropenia (83%), lymphopenia (67%), leukopenia (33%), and thrombocytopenia (17%). Patients receiving venetoclax monotherapy achieved an ORR of 100%, including a complete remission (CR) rate of 17%. Patients receiving combination therapy had an ORR of 67% and a CR rate of 50%. The venetoclax pharmacokinetics profile in Japanese patients was similar to that of Western patients. Venetoclax 400 mg/day monotherapy or in combination with rituximab was well-tolerated and induced promising responses in Japanese patients with R/R CLL/SLL. Although patient numbers were small, the safety profile was largely consistent with other Western studies. Clinical trial registration: clinicaltrials.gov; NCT02265731.
Similar content being viewed by others
Data availability
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and Clinical Study Reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. This clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit the following link: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html.
References
O’Brien S, del Giglio A, Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood. 1995;85(2):307–18.
Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164(4):536–45.
Zhao Y, Wang Y, Ma S. Racial differences in four leukemia subtypes: comprehensive descriptive epidemiology. Sci Rep. 2018;8(1):548.
Chan TS, Lee YS, Del Giudice I, Marinelli M, Ilari C, Cafforio L, et al. Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients. Oncotarget. 2017;8(15):25455–68.
Wu SJ, Lin CT, Agathangelidis A, Lin LI, Kuo YY, Tien HF, et al. Distinct molecular genetics of chronic lymphocytic leukemia in Taiwan: clinical and pathogenetic implications. Haematologica. 2017;102(6):1085–90.
Takizawa J, Gruber M, Suzuki R, Nakamura N, Hoermann G, Muellauer L, et al. Comparative analysis of Japanese and European typical CLL patients. Blood. 2016;128(22):5564.
Kim JA, Hwang B, Park SN, Huh S, Im K, Choi S, et al. Genomic profile of chronic lymphocytic leukemia in korea identified by targeted sequencing. PLoS ONE. 2016;11(12):e0167641.
Tobinai K, Ogura M, Ishizawa K, Suzuki T, Munakata W, Uchida T, et al. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. Int J Hematol. 2016;103(1):86–94.
Ogawa Y, Ogura M, Suzuki T, Ando K, Uchida T, Shirasugi Y, et al. A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Int J Hematol. 2013;98(2):164–70.
Brown JR. The treatment of relapsed refractory chronic lymphocytic leukemia. Hematology Am SocHematolEduc Program. 2011;2011:110–8.
Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200–11.
Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749–55.
Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18(3):297–311.
Bottcher S, Hallek M, Ritgen M, Kneba M. The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time? Hematol Oncol Clin N Am. 2013;27(2):267–88.
Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062–7.
Del Gaizo MV, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J ClinInvestig. 2007;117(1):112–21.
Leverson JD, Sampath D, Souers AJ, Rosenberg SH, Fairbrother WJ, Amiot M, et al. Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax. Cancer Discov. 2017;7(12):1376–93.
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8.
Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH, et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015;100(8):e302–6.
Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22.
Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–78.
Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19):1973–80.
Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18(2):230–40.
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–20.
Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–36.
Yamamoto K, Hatake K, Fukuhara N, Kusumoto S, Nagai H, Kobayashi Y, et al. A phase 1 study evaluating the safety and pharmacokinetics (PK) of venetoclax (Ven) in Japanese patients (Pts) with non-hodgkin lymphoma (NHL) and multiple myeloma (MM). Haematologica. 2017;102(s2):1.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56.
National Institutes of Health. National Cancer Institute: common terminology criteria for adverse events (CTCAE), version 4.03 2010. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 18 Oct 2020.
Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.
Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, et al. Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed/refractory chronic lymphocytic leukemia. Clin Cancer Res. 2018;24(18):4371–9.
Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–54.
Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. 2015;7(279):279ra40.
Salem AH, Agarwal SK, Dunbar M, Enschede SL, Humerickhouse RA, Wong SL. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma. J ClinPharmacol. 2017;57(4):484–92.
Salem AH, Dunbar M, Agarwal SK. Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia. Anticancer Drugs. 2017;28(8):911–4.
Freise KJ, Dunbar M, Jones AK, Hoffman D, Enschede SL, Wong S, et al. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis. Cancer Chemother Pharmacol. 2016;78(4):847–53.
Freise KJ, Jones AK, Menon RM, Verdugo ME, Humerickhouse RA, Awni WM, et al. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy. Hematol Oncol. 2017;35(4):679–84.
Freise KJ, Jones AK, Eckert D, Mensing S, Wong SL, Humerickhouse RA, et al. Impact of venetoclax exposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia. ClinPharmacokinet. 2017;56(5):515–23.
Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL study group. J Clin Oncol. 2016;34(31):3758–65.
Acknowledgements
The authors and AbbVie/Genentech would like to thank the patients and their families/caregivers; study investigators and support staff; Norio Komatsu (Juntendo University School of Medicine, Tokyo), Noriko Usui (The Jikei University School of Medicine, Dai-San Hospital, Tokyo), and Sadao Aoki (Niigata University of Pharmacy and Applied Life Sciences), all members of the Data and Safety Monitoring Committee; and Dalia Majumdar, PhD and Mrinal Y. Shah, PhD for medical writing support, both employees of AbbVie, Inc. This study was funded by AbbVie and Genentech.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Koji Izutsu: Honoraria from Eisai, MSD, Kyowa-Kirin, Takeda, Janssen, Dainihon Sumitomo, Mundipharma, Nihon Mediphysics, Chugai, AbbVie, AstraZeneca, Bayer, Ono, Celgene; research funding from Eisai, Janssen, Mundipharma, Chugai, AstraZeneca, AbbVie, Bayer, Ono, Gilead, Zenyaku, Celgene, Solasia, Symbio, Astellas, Astellas Amgen, Bayer, Daiichi Sankyo. Kazuhito Yamamoto: Research funding from AbbVie, ARIAD Pharmaceuticals, AstraZeneca, Bayer, Celgene, Chugai, Eisai, Gilead Sciences, Incyte, MSD, Mundipharma, Nippon Shinyaku, Novartis, Ono, Solasia Pharma, SymBio, Takeda, Zenyaku; honoraria from Chugai, Mundipharma, Takeda. Koji Kato: Honoraria from Chugai, Takeda, MSD, Kyowa-Kirin, Janssen, Celgene, Ono, Mundi, Dainippon-Sumitomo; consulting or advisory role for Novartis, Eisai, Janssen, Celgene; research funding from Chugai, Takeda, Kyowa-Kirin, AbbVie, Novartis, Eisai, Janssen, Celgene, Ono. Takayuki Ishikawa: Investigator in AbbVie-sponsored clinical trials. Noriko Fukuhara: Research funding from AbbVie, Bayer, Eisai, Gilead, Janssen, Ono, Takeda; honoraria from Kyowa Hakko Kirin. Yasuhito Terui: Honoraria from Chugai, Takeda, Janssen, Celgene, Ono, Mundi, Novartis, Eisai, Takeda; research funding from BMS. Ilseung Choi: Investigator in AbbVie-sponsored clinical trials. Kathryn Humphrey: Employee of Roche and may own stock or stock options. Su Young Kim, Sumiko Okubo, Natsumi Ogawa, Yasuko Nishimura, Ahmed Hamed Salem: Employees of AbbVie and may own stock or stock options. Dai Maruyama: Research funding from Chugai Pharma, Ono Pharmaceutical, Celgene, Janssen, GlaxoSmithKline, Eisai, Mundipharma, Takeda, AbbVie, MSD, Astellas Pharma, Amgen, Astellas, BioPharma, Otsuka, Novartis, Nippon Boehringer Ingelheim, Pfizer, Solasia Pharma, Bayer, Zenyaku Kogyo, AstraZeneca; honoraria from Zenyaku Kogyo, Eisai, Takeda, Mundipharma, Janssen, Kyowa Hakko Kirin, Celgene, Fujifilm, Chugai Pharma, MSD, Ono Pharmaceutical. AbbVie/Genentech: AbbVie and Genentech sponsored the study (NCT02265731), contributed to the study design, analysis, interpretation of the data, and participated in the writing, review, and approval of the manuscript. All authors had access to data. Venetoclax (ABT-199/GDC-0199) is being developed in collaboration between AbbVie and Genentech.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Izutsu, K., Yamamoto, K., Kato, K. et al. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Int J Hematol 113, 370–380 (2021). https://doi.org/10.1007/s12185-020-03024-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-020-03024-3